Therapy (HBV)
"Safety and Efficacy of Interferon Retreatment in Children With Chronic Hepatitis B."
Published in Hepatitis Weekly, July 13th, 1998
According to the authors' abstract of an article published in European Journal of Pediatrics, "More than 50% of children with chronic hepatitis B do not respond to treatment with alpha-interferon. Since these patients continue to display high viral replication and progressive liver disease, retreatment should be considered. To date it has not been well evaluated whether a second course of treatment could increase the response rate. In two alpha-interferon retreatment trials in adult patients the response rate, defined by seroconversion from HBeAg to anti-HBe, ranged between 11% and 44%. One beta-interferon retreatment study in children reported a seroconversion rate of 32%. ...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (1998-07-13)
More Articles from Hepatitis Weekly
- Testing (HCV)
Single ELISA is Adequate, Even When Results are Weak - Animal Models (HBV)
Woolly Monkey May Be Long Sought Primate Model - Diagnostics
Autoimmune Hepatitis/Cholangiography Overlap Syndrome Reported - Therapy (HCV)
Depression May Be Worse with Certain Interferons - Virology (HCV)
p21 Protein is Component of Hepatitis C Viral Particles - Conference Coverage
CDC Shows Allergic Reactions Linked to Vaccine Gelatin - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
